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Abstract 
CD44 is a single-pass cell surface glycoprotein that is distinguished as the first molecule used to identify 
cancer stem cells in solid tumors based on its expression. In this regard, the CD44high cell population 
demonstrates not only the ability to regenerate a heterogeneous tumor, but also the ability to 
self-regenerate when transplanted into immune-deficient mice. However, the exact role of CD44 in 
cancer stem cells remains unclear in part because CD44 exists in various isoforms due to alternative 
splicing.  
Methods: Gain- and loss-of-function methods in different models were used to investigate the effects of 
CD44 on breast cancer stemness. Cancer stemness was analyzed by detecting SOX2, OCT4 and 
NANOG expression, ALDH activity, side population (SP) and sphere formation. Glucose consumption, 
lactate secretion and reactive oxygen species (ROS) levels were detected to assess glycolysis. Western 
blot, immunohistochemical staining, ELISA and TCGA dataset analysis were performed to determine the 
association of CD44ICD and PFKFB4 with clinical cases. A PFKFB4 inhibitor, 5MPN, was used in a 
xenograft model to inhibit breast cancer development. 
Results: In this report, we found that the shortest CD44 isoform (CD44s) inhibits breast cancer 
stemness, whereas the cleaved product of CD44 (CD44ICD) promotes breast cancer stemness. 
Furthermore, CD44ICD interacts with CREB and binds to the promoter region of PFKFB4, thereby 
regulating PFKFB4 transcription and expression. The resultant PFKFB4 expression facilitates the 
glycolysis pathway (vis-à-vis oxidative phosphorylation) and promotes stemness of breast cancer. In 
addition, we found that CD44ICD and PFKFB4 expressions are generally up-regulated in the tumor 
portion of breast cancer patient samples. Most importantly, we found that 5MPN (a selective inhibitor of 
PFKFB4) suppresses CD44ICD-induced tumor development. 
Conclusion: CD44ICD promotes breast cancer stemness via PFKFB4-mediated glycolysis, and 
therapies that target PFKFB4 (e.g., 5MPN therapy) may lead to improved outcomes for cancer patients. 
Key words: PFKFB4, CD44ICD, stemness, glucose metabolism 
Introduction 
CD44 is a type I transmembrane glycoprotein 
that plays a role in cell proliferation, differentiation, 
adhesion, migration, and survival [1-3]. More 
importantly, CD44 acts as a cell surface marker to 
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identify, isolate, and enrich cancer stem cells in many 
different types of cancer including breast, colon, liver, 
ovarian, and pancreatic cancers [4]. In addition, CD44 
undergoes a two-step proteolytic cleavage in the 
ecto-domain and intramembrane domain that releases 
an intracellular domain (CD44ICD) [5]. Subsequently, 
CD44ICD then interacts with various stemness 
factors, which include SOX2, NANOG, and OCT4 in 
breast cancer [6]. 
Cancer stem cells encompass a small distinct 
population of cancer cells that possess properties of 
self-renewal and differentiation into multiple cell 
types [7]. The presence of cancer stem cells serves as 
the primary driver for cancer recurrence or relapse [8]. 
A number of reports have revealed that cancer stem 
cells preferentially utilize the glycolysis pathway 
rather than oxidative phosphorylation to maintain 
homeostasis even in the face of oxygen abundance 
[9-12].  
The 6-phosphofructo-2-kinase/fructose-2, 
6-biphosphatase 4 (PFKFB4) enzyme belongs to a 
family of bi-functional enzymes that adjusts the 
balance between 6-phosphofructose (F6P) and 
fructose-2, 6-biphosphate (F26P). PFKFB4 not only 
catalyzes the synthesis of F26P from F6P and ATP, but 
also catalyzes the hydrolysis of F26P to F6P and 
orthophosphate. Consequently, PFKFB4 dynamically 
regulates the levels of F26P, which is a powerful 
allosteric activator of phosphofructokinase1 (PFK1), a 
critical enzyme in the glycolysis pathway [13].  
In this study, we investigated the role of CD44 
on breast cancer stemness from a glucose metabolism 
point of view. We found the following: 1) CD44s 
inhibits breast cancer stemness, but CD44ICD 
promotes breast cancer stemness; 2) CD44ICD 
promotes breast cancer stemness via 
PFKFB4-mediated glycolysis; 3) CD44ICD interacts 
with the promoter region of PFKFB4, which depends 
on CREB; 4) CD44ICD expression and PFKFB4 
expression increase in the tumor portion of breast 
cancer patient samples; 5) 5MPN (a specific inhibitor 
of PFKFB4) suppresses breast cancer development. 
Our findings suggest a potential strategy whereby 
5MPN either as a single agent or in combination with 
currently available treatments may lead to an 
improved therapeutic outcome for cancer patients. 
Methods 
Cell culture 
Human breast cancer cell lines MDA-MB-231, 
MCF7, SUM159 and MDA-MB-468 were cultured in 
high glucose DMEM (Biological Industries, Kibbutz 
Beit-Haemek, Israel) containing 10% FBS (Biological 
Industries) and 100 U/mL penicillin-streptomycin 
(Hyclone, Logan, UT, USA). Human breast cancer cell 
line ZR-75-1 cells were cultured in RPMI 1640 
(Biological Industries) containing 10% FBS, 2.5 g/L 
glucose (Sigma-Aldrich, St. Louis, MO, USA), 1.5 g/L 
sodium bicarbonate (Thermo Fisher Scientific, 
Waltham, MA, USA), 0.1 g/L sodium pyruvate 
(Thermo Fisher Scientific) and 100 U/mL 
penicillin-streptomycin. Human breast cancer cell line 
SKBR3 cells were cultured in DMEM containing 
10% FBS, 1.5 g/L sodium bicarbonate and 100 U/mL 
penicillin-streptomycin. Murine breast cancer cell 
lines EMT6 and EO771 cells were cultured in RPMI 
1640 containing 10% FBS and 100 U/mL 
penicillin-streptomycin. Cells were maintained at 37 
°C in a humidified atmosphere with 5% CO2. 
Tumor and blood specimens 
Human breast cancer samples and blood were 
obtained from the Chinese PLA General Hospital. All 
tumor samples were invasive ductal carcinoma of the 
breast that were confirmed histologically. This study 
was approved by the institutional ethics committees 
of PLA General Hospital. All patients signed a 
consent form. 
Vector construction and stable cell lines 
establishment 
For gene overexpression, DNA sequences 
encoding human CD44s and PFKFB4 were 
PCR-amplified from MDA-MB-231 cDNA and cloned 
into the pLV-EF1α-MCS-IRES-Bsd plasmid (Biosettia, 
San Diego, CA, USA). DNA sequences encoding 
CD44s-Flag, CD44∆67, CD44ICD and CD44ICD-Flag 
were PCR-amplified from CD44s overexpression 
plasmid and cloned into the 
pLV-EF1α-MCS-IRES-Bsd plasmid. To generate 
kinase dead K173A mutant of PFKFB4, PFKFB4-mut 
primers were used. For gene silencing, short hairpin 
RNAs (shRNAs) targeting human CD44, PFKFB4, 
CREB and murine Cd44 were cloned into the 
pLV-H1-EF1α-puro plasmid (Biosettia). The 
lentiviruses carrying the overexpression vectors, gene 
silencing vectors or empty vectors were produced 
according to manufacturer’s instruction. 
Lentivirus-containing medium was applied to cells in 
the presence of 8 μg/mL polybrene for 48 h, prior to 
selection with 10 μg/mL blasticidin or 1 μg/mL 
puromycin for a week to establish stable cell lines. The 
primers and shRNAs are listed in Table S1, and the 
CD44s cDNA sequence is in Supplementary Material. 
CRISPR/Cas9 KO system 
20 nucleotides guide sequences were designed 
using the https://chopchop.rc.fas.harvard.edu/ 
webpage. Single-guide RNAs (sgRNAs) were cloned 
into LentiCRISPR vector (#51761, Addgene, 
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Cambridge, MA, USA). Lentivirus was prepared 
using 293T cells, and lentiviral-rich conditioned 
media was applied to EO771 cells in the presence of 
polybrene for 48 h, prior to selection with 1 μg/mL 
puromycin for 3 days. Then, cells were seeded into 
96-well plates at an average density of 0.4 cells/well. 
Single clones were expanded and screened by 
immunoblotting and genomic sequencing. The 
murine Cd44 sgRNAs were: 
oligo1:5’-caccGCAGGTTACATTCAAATCTG-3’ and 
oligo2: 5’-aaacCAGATTTGAATGTAACCTGC-3’. 
Cell viability 
Cell viability was determined using cell counting 
kit-8 (CCK-8; Dojindo Molecular Technologies, 
Rockville, MD, USA). Briefly, cells were seeded into 
96-well plates at a density of 3×103 cells/well. CCK-8 
reagent was added into the wells at indicated time 
points and incubated at 37 °C for 2 h. The absorbance 
was measured at 450 nm in a microplate reader 
(Promega, Madison, WI, USA).  
Apoptosis assay 
About 1×106 cells were seeded into each well of a 
6-well plate and treated with 2 μg/mL cisplatin 
(Sigma-Aldrich) for 48 h. Cell apoptosis was 
quantified using FITC Annexin V Apoptosis 
Detection Kit (BD Biosciences, San Jose, CA, USA) 
according to the manufacturer’s instructions. 
Aldefluor assay 
ALDEFLUOR kit (STEMCELL Technologies, 
Vancouver, Canada) was used to measure ALDH 
enzymatic activity. Briefly, 2.5×105 cells were 
suspended in ALDRFLUOR assay buffer containing 
ALDH1 substrate and incubated at 37 °C for 45 min. 
Stained cells were analyzed on FACS Calibur flow 
cytometer (BD Biosciences), and data analysis was 
performed using Flowjo software (Tree Star, Inc., 
Ashland, OR, USA). DEAB, a specific ALDH inhibitor, 
served as a negative control.  
Side population assay 
Cells were suspended at a density of 1×106 
cells/mL and then incubated with 5 μg/mL Hoechst 
33342 (Sigma-Aldrich) at 37 °C for 60 min. Samples 
were analyzed on LSRFortessa flow cytometer (BD 
Biosciences), and data analysis was performed using 
Flowjo software (Tree Star, Inc.). Verapamil 
(Sigma-Aldrich) served as a negative control.  
Sphere formation assay 
About 1×103 cells were seeded onto ultra-low 
attachment 48-well plates (Corning, NY, USA) in the 
presence of serum-free DMEM or RPMI 1640 
supplemented with 1× B27 (Invitrogen, Carlsbad, CA, 
USA), 20 ng/mL human epidermal growth factor 
(Invitrogen), and 20 ng/mL basic fibroblast growth 
factor (Invitrogen) for 7 days. Then, the spheres were 
counted. 
Measurement of glucose consumption and 
lactate secretion 
ZR-75-1 and SKBR3 cells were seeded in 96-well 
plates at a density of 1×104 cells/well and incubated 
in low glucose RPMI 1640 or DMEM, respectively. 
Twenty-four hours later, glucose concentrations in the 
media were determined using a glucose colorimetric 
assay kit (BioVision, Milpitas, CA, USA) following the 
manufacturer’s instructions. For assessment of lactate 
secretion, cells were cultured in RPMI 1640 or DMEM, 
respectively. Thirty-six hours later, lactate secretion 
was assessed using a lactate colorimetric assay kit 
(BioVision) according to the manufacturer’s protocol. 
Measurement of reactive oxygen species 
Reactive oxygen species (ROS) were detected by 
staining the cells with the ROS-sensitive probe 
CM-H2DCFDA (Thermo Fisher Scientific) according 
to the manufacturer’s instructions. Briefly, cells were 
incubated with 5 μM CM-H2DCFDA/ PBS at 37 °C 
for 30 min and washed twice with PBS. The mean 
fluorescence intensity of CM-H2DCFDA was 
determined by FACS Calibur flow cytometer (BD 
Biosciences) as an indicator of ROS production.  
Quantitative RT-PCR 
Total RNA was extracted using TRIZOL 
(Invitrogen), and reverse transcription was performed 
using the TransScript First-Strand cDNA Synthesis 
SuperMix Kit (TransGen Biotech, Beijing, China) 
according to the manufacturer’s recommendations. 
qPCR was performed using a CFXTM real-time 
thermal cycler (Bio-Rad, Hercules, CA, USA) using a 
TransStart Top Green qPCR SupperMix kit (TransGen 
Biotech). The primers used are listed in Table S2. 
Western blot 
Detection of protein expression by western blot 
was carried out according to the established protocols 
described previously [14]. Western blot was 
performed using the following antibodies: SOX2 
(sc-20088) and β-actin (sc-47778) antibodies were 
purchased from Santa Cruz Biotechnology (Dallas, 
Texas, USA). OCT4 (ab19857), NANOG (ab80892) and 
PFKFB4 (ab137785) antibodies were purchased from 
Abcam (Cambridge, UK). CD44 (3570), Flag (8146s) 
and CREB (9197s) antibodies were purchased from 
Cell Signaling Technology (Danvers, MA, USA). 
Enzyme-linked immunosorbent assay (ELISA) 
Soluble CD44 (sCD44) in human serum was 
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quantified using the CD44std (Human) ELISA kit 
(Abnova, Walnut, CA, USA) according to the 
manufacturer’s protocol. Briefly, the serum was 
added in duplicate to wells of microtiter plates coated 
with horseradish peroxidase-conjugated CD44s. Then, 
the absorbance was measured at 450 nm using a 
microplate reader (Promega). 
Chromatin immunoprecipitation (ChIP) 
ChIP assay was performed using an EZ-ChIP kit 
(Millipore Corp, Billerica, MA, USA) following the 
manufacturer’s instructions. In brief, cells grown in 10 
cm dishes were cross-linked with 1% formaldehyde 
for 10 min at room temperature and the reaction was 
stopped with glycine. After sonication and 
centrifugation, the supernatant was collected for 
anti-Flag immunoprecipitation. Anti-RNA 
polymerase and anti-rabbit IgG were also used as a 
positive or negative control, respectively. 
Semi-quantitative RT-PCR was performed to detect 
DNA fragments of the PFKFB4 promoter region. The 
primers used are listed in Table S3.  
Co-immunoprecipitation 
Total proteins were extracted from ZR-75-1 cells 
expressing CD44s-Flag or CD44ICD-Flag and protein 
concentrations were determined by BCA protein 
assay. Briefly, 500 μg of cell lysates were incubated 
with 5 μg of anti-Flag antibody (Cell Signaling 
Technology) overnight at 4 °C with rotation. The 
protein-antibody mixture was then incubated with 
pre-washed protein G-agarose beads (CWBIO, 
Beijing, China) for an additional 4 h. The beads were 
washed twice with lysis buffer and resuspended in 2× 
Laemmli buffer. After protein denature, 5 μL of the 
beads supernatant was separated on SDS-PAGE gel 
for western blot to detect FLAG, SOX2, Oct4, Nanog, 
and CREB. 10 μg of protein lysate was subjected to 
western blot as an input. 
Dual-luciferase reporter assay 
ZR-75-1 cells were co-transfected with human 
PFKFB4 promoter firefly luciferase and CD44ICD 
expression plasmids using Lipofectamine Reagent 
(Invitrogen). Thirty-six hours later, luciferase activity 
was measured using the Dual-Luciferase Reporter 
Assay System (Promega) according to the 
manufacturer’s protocol. Luciferase activity was 
normalized to Renilla luciferase activity. 
Animal experiments 
ZR-75-1 cells (2×106) expressing either CD44s, 
CD44ICD, or control vector were injected into the 
second mammary fat pad of 8-week-old female 
NOD/ SCID mice (n=5 per group). Also, 5×105 EO771 
cells expressing CD44KO, CD44KO+CD44s, 
CD44KO+CD44ICD or WT, respectively, were 
injected into the second mammary fat pad of 
8-week-old female C57BL/6 mice. Tumor volume was 
measured twice a week and calculated using the 
standard formula: length × width2 / 2. To examine the 
lung metastases foci, lung tissues were fixed with 4% 
PFA for 24 h and stained with hematoxylin and eosin. 
Metastasis was evaluated by counting the metastatic 
foci in three randomly selected fields. Mice were 
purchased from Vital River Laboratory Animal 
Technology Co. Ltd (Beijing, China) and maintained 
in a specific pathogen-free facility. Animal use 
complied with Nankai University Animal Welfare 
Guidelines. All of the animal experiments were 
approved by the Nankai University Animal Care and 
Use Committee. 
Animal experiment with 5MPN 
CD44 knockout EO771 cells infected with 
lentivirus encoding CD44ICD (CD44KO+CD44ICD) 
or control virus (CD44KO+MCS) were injected into 
the fourth fat pad of 8-week-old female C57BL/6 mice 
(5×105 cells/mice; n=5 per group). When the tumor 
size reached about 100 mm3, mice were treated with 
120 mg/kg 5MPN (a specific inhibitor of PFKFB4) 
every two days by oral gavage for 10 days. Tumor 
size, tumor weight and lung metastases were 
evaluated using the methods mentioned above. 
Statistical analysis 
Kaplan–Meier survival curves were created 
using the log-rank test for TCGA data to compare the 
PFKFB4 high group with the PFKFB4 low group. All 
data were analyzed using GraphPad Prism5 software 
(GraphPad Software, San Diego, CA, USA). Results 
are expressed as mean ± SD with the exception of 
human sample and animal model data, which are 
expressed as mean ± SEM. P values were calculated 
using a two-tailed Student’s t-test (two groups) or 
one-way ANOVA (more than 2 groups) unless 
otherwise noted. The results were considered 
statistically significant when *P<0.05, **P<0.01, 
***P<0.001. 
Results 
CD44s inhibits breast cancer stemness, 
whereas CD44ICD promotes breast cancer 
stemness 
CD44 serves as a cell surface marker for cancer 
stem cells in many types of cancer, including breast, 
ovarian, lung, and pancreatic cancers. However, the 
exact role of CD44 on cancer cell stemness remains 
unclear. Besides the standard isoform of CD44 
(CD44s), CD44 also expresses as other isoforms due to 
inclusion of variant exons or alternative splicing. In 
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this study, we clarified the role of CD44s, CD44∆67, 
and CD44ICD isoforms on breast cancer stemness. 
The CD44∆67 isoform has a truncated cytoplasmic 
domain that includes exon19 instead of exon20 and 
occurs naturally [15]. 
We first ectopically expressed CD44s, CD44∆67, 
and CD44ICD in CD44-negative ZR-75-1 human 
breast cancer cells (Figure 1A and Figure S1A) and 
then analyzed the effect of their ectopic expression on 
localization, cell proliferation, and apoptosis. Our 
results indicated that reconstituted CD44s and 
CD44∆67 localize on the cell membrane, whereas 
reconstituted CD44ICD localizes in the nucleus 
(Figure 1B). A similar localization pattern also occurs 
in CD44-negative SKBR3 human breast cancer cells 
(Figure S1B-C). In addition, our results indicated that 
CD44s ectopic expression inhibits cell proliferation in 
ZR-75-1 breast cancer cells. However, CD44ICD and 
CD44∆67 ectopic expression stimulates cell 
proliferation in ZR-75-1 breast cancer cells. The 
pro-proliferation effect of CD44∆67 is not as dramatic 
when compared to CD44ICD ectopic expression 
(Figure 1C and Figure S1D). Our results also 
indicated that CD44s ectopic expression advances 
apoptosis in ZR-75-1 breast cancer cells. However, 
CD44ICD and CD44∆67 ectopic expression 
suppresses apoptosis in ZR-75-1 breast cancer cells. 
The anti-apoptosis effect of CD44∆67 is not as 
dramatic when compared to CD44ICD ectopic 
expression (Figure 1D). Therefore, we focused our 
further investigation on the role of CD44s and 
CD44ICD on breast cancer stemness. 
We next explored the role of CD44s and 
CD44ICD on various stem cell markers. On one hand, 
our results showed that CD44s ectopic expression 
decreases SOX2, OCT4, and NANOG expression at 
both mRNA and protein levels in ZR-75-1 and SKBR3 
breast cancer cells (Figure 1E-F and Figure S1E). In 
addition, CD44s ectopic expression attenuates the 
percentage of ALDEFLUOR+ cells in ZR-75-1 and 
SKBR3 breast cancer cells (Figure 1G). CD44s ectopic 
expression also decreases the percent side population 
and sphere formation ability (Figure S1F-G). On the 
other hand, our results showed that CD44ICD ectopic 
expression increases SOX2, OCT4, and NANOG 
expression at both mRNA and protein levels in 
ZR-75-1 and SKBR3 breast cancer cells (Figure 1E-F 
and Figure S1H). In addition, CD44ICD ectopic 
expression enhances the percentage of ALDEFLUOR+ 
cells in ZR-75-1 and SKBR3 breast cancer cells (Figure 
1G). CD44ICD ectopic expression also increases the 
percent side population and sphere formation ability 
(Figure S1I-J). We observed a similar effect of CD44s 
versus CD44ICD on the percent side population and 
sphere formation ability of MDA-MB-231 cells (Figure 
S1K-L). 
Since previous reports have indicated that 
CD44ICD associates and activates stem cell markers 
(i.e., NANOG, OCT4, SOX2) [6, 16], we then examined 
interaction of stem cell markers with CD44s versus 
CD44ICD. The co-immunoprecipitation results 
showed that CD44s interacts mainly with SOX2 (not 
OCT4 or NANOG) and that CD44ICD interacts with 
SOX2, OCT4, and NANOG in ZR-75-1 breast cancer 
cells (Figure 1H). The CD44ICD interaction with 
SOX2, OCT4, and NANOG may partially explain why 
CD44ICD plays a more impactful role on stemness 
than CD44s. 
The ZR-75-1 xenograft mouse model results 
showed that CD44s ectopic expression decreases 
tumor volume and metastatic foci in the lung (Figure 
1I-J). However, CD44ICD ectopic expression increases 
tumor volume and metastatic foci in the lung (Figure 
1I-J). These in vivo xenograft mouse model results 
confirm our in vitro results that CD44s plays an 
inhibitory role, whereas CD44ICD plays a stimulatory 
role, in tumorigenesis of breast cancer. 
Our studies also showed that CD44 knockdown 
increases Sox2, Oct4, and Nanog expression at both 
mRNA and protein levels in MDA-MB-231 and EMT6 
breast cancer cells (Figure S2A-B). CD44 knockdown 
also increases the percent side population and sphere 
formation ability (Figure S2C-D). 
To further confirm the above findings, we 
generated a CD44 knockout (CD44KO) murine 
mammary carcinoma EO771 cell line using 
CRISPR/Cas9 technique (Figure 2A). We found that 
CD44KO increases Sox2, Oct4, and Nanog expression 
at both mRNA and protein levels, which confirmed 
our previously mentioned findings (Figure 2B-C). 
CD44KO also increases the percent side population 
and sphere formation ability (Figure 2D-E). In 
addition, CD44KO increases tumor volume, tumor 
weight, and metastatic foci in the lung (Figure 2F-I). 
We also found that reconstituted CD44s in 
CD44KO-EO771 cells decreases tumor volume, tumor 
weight, and metastatic foci in the lung (Figure 2F-I), 
whereas, reconstituted CD44ICD in CD44KO-EO771 
cells increases tumor volume, tumor weight, and 
metastatic foci in the lung (Figure 2F-I). We observed 
that re-constitution of CD44ICD in CD44KO-EO771 
cells leads to an increase in stem cell marker (i.e., 
Sox2, Oct4, Nanog) mRNA and protein expression 
(Figure S2E-F) and an increase in sphere formation 
ability (Figure S2G). These results using 
CD44KO-EO771 cells further confirm our earlier 
results that CD44s plays an inhibitory role, whereas 
CD44ICD plays a stimulatory role for tumorigenesis 
in breast cancer. 
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Figure 1. CD44ICD promotes stem cell-like characteristics of breast cancer cells. (A) Western blot analysis of CD44s, CD44∆67 and CD44ICD expression in ZR-75-1 cells. 
β-actin serves as a loading control. (B) Immunofluorescence staining of CD44s, CD44∆67 and CD44ICD in ZR-75-1 cells. (C) CCK-8 assay of ZR-75-1 cells reconstituted with CD44s, 
CD44∆67, and CD44ICD. (D) PI-Annexin V double staining assay of ZR-75-1 cells reconstituted with CD44s, CD44∆67, or CD44ICD. (E) Quantitative PCR (qPCR) analysis of SOX2, OCT4 
and NANOG expression in ZR-75-1 and SKBR3 cells. (F) Western blot analysis of SOX2, OCT4 and NANOG expression in ZR-75-1 and SKBR3 cells. (G) Flow cytometric analysis of ALDH 
activity in ZR-75-1 and SKBR3 cells reconstituted with CD44s or CD44ICD. (H) Co-immunoprecipitation of CD44ICD or CD44s ZR-75-1 cells. The western blot in the left panel qualitatively 
shows that CD44ICD (anti-Flag) co-immunoprecipitated with SOX2, OCT4 and NANOG in CD44ICD ZR-75-1 cells. The western blot in the right panel qualitatively shows that CD44s 
(anti-Flag) co-immunoprecipitated with SOX2, but not OCT4 or NANOG in CD44s ZR-75-1 cells. Mouse IgG antibody serves as a negative control. (I) Tumor volume of ZR-75-1 xenograft 
mouse model. (J) Representative images of lung metastasis in ZR-75-1 xenograft mouse model (left panel). Quantification of total tumor metastasis to the lung based on incidence of 
dissemination from primary tumors (right panel). One-way ANOVA was used for statistical analysis and data are shown as mean ± SD except for (I-J) (mean ± SEM). Data are representative 
of at least three independent experiments. 
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Figure 2. CD44 knockout enhances stem cell-like characteristics of breast cancer cells. (A) Illustration of the sgRNA genomically targeted sequence in mouse Cd44 locus. 
Constant exons are depicted as green bars, variant exons are depicted as red bars, and introns are depicted as black lines. PAM: protospacer adjacent motif. (B) qPCR analysis of Sox2, Oct4 
and Nanog expression in CD44 knockout (CD44KO) EO771 cells versus wild type controls (WT). Establishment of CD44KO EO771 stable cell line was confirmed by western blot (inset). 
(C) Western blot analysis of SOX2, OCT4, and NANOG expression in CD44KO EO771 cells versus WT. β-actin serves as a loading control. (D) Flow cytometric analysis of side population 
(SP) in CD44KO EO771 cells versus WT. (E) Sphere formation ability of EO771 cells in CD44KO EO771 cells versus WT. (F) Western blot analysis of CD44s or CD44ICD re-expression 
in CD44KO EO771 cells. (G) Tumor volume of EO771-derived CD44 cell lines injected into C57BL/6 mice. (H) Tumor weight of EO771-derived CD44 cell lines injected into C57BL/6 mice. 
(I) Representative images of lung metastasis (left panel). Quantification of total tumor metastasis to the lung based on incidence of dissemination from primary tumors (right panel). For (D-E), 
Student’s t-test was used for statistical analysis and data are shown as mean ± SD. For (G-I), one-way ANOVA was used for statistical analysis and data are shown as mean ± SEM. Data are 
representative of at least three independent experiments. 
 
CD44ICD promotes glycolysis and 
up-regulates PFKFB4 expression by binding to 
its promoter region 
A distinctive property associated with cancer 
stem cells (CSCs) is that CSCs show high glycolytic 
activity but low oxidative phosphorylation activity. 
The characteristics of glycolysis include not only 
increased glucose consumption and lactate secretion, 
but also a decreased production of reactive oxygen 
species (ROS) [17]. To verify the impact of CD44ICD 
on breast cancer stemness, we examined glucose 
consumption, lactate secretion, and ROS production. 
Our results indicate that CD44ICD ectopic expression 
not only increases glucose consumption and lactate 
secretion, but also decreases ROS production (Figure 
3A-C). This finding strongly suggests that CD44ICD 
promotes breast cancer stemness from a metabolic 
perspective.  
In this regard, we found that CD44ICD ectopic 
expression specifically up-regulates PFKFB4 (a key 
enzyme in the glycolysis pathway) mRNA levels, but 
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not ENO2 and ALDOC mRNA levels (Figure S3A). In 
addition, PFKFB4 mRNA levels increase in five 
different human breast cancer cell lines when cultured 
in spheres compared to monolayer (Figure S3B). 
Thus, we investigated whether PFKFB4 is involved in 
CD44ICD-mediated breast cancer stemness. Our 
results showed that CD44ICD ectopic expression 
significantly up-regulates PFKFB4 expression at both 
mRNA and proteins levels in ZR-75-1 and SKBR3 
breast cancer cells (Figure 3D). Moreover, our results 
showed that CD44ICD interacts with the PFKFB4 
promoter region using the ChIP assay (Figure 3E) and 
that CD44ICD induces PFKFB4 transcription using a 
luciferase reporter system (Figure 3F). Previous 
studies from other laboratories have indicated that 
CD44ICD interacts with the CREB transcription factor 
in thyroid cancer cells [18]. Our study confirmed that 
CD44ICD interacts with the CREB transcription factor 
in ZR-75-1 breast cancer cells (Figure 3G). In addition, 
we found that CREB knockdown decreases 
CD44ICD-induced PFKFB4 transcription (Figure 3H). 
This suggests that CD44ICD may function as a 
co-transcription factor and interact with CREB to 
regulate PFKFB4 transcription. 
 
 
Figure 3. CD44ICD promotes glycolysis and up-regulates PFKFB4 expression. (A) Analysis of glucose uptake in CD44ICD ZR-75-1 and SKBR3 cells. (B) Analysis of lactate 
secretion in CD44ICD ZR-75-1 and SKBR3 cells. (C) Analysis of ROS levels in CD44ICD ZR-75-1 and SKBR3 cells. (D) Analysis of PFKFB4 expression by qPCR and western blot in CD44ICD 
ZR-75-1 and SKBR3 cells. (E) ChIP-PCR analysis of Flag marks (CD44ICD) at the PFKFB4 promoter region in ZR-75-1 cells. Schematic diagram of PFKFB4 promoter regions (top). Mouse IgG 
serves as a negative control. (F) Relative firefly-luciferase activity of PFKFB4 in CD44ICD ZR-75-1 cells. Firefly luciferase activity was normalized to Renilla luciferase activity for all samples to 
yield relative luciferase activity. (G) Co-immunoprecipitation in CD44ICD ZR-75-1 cells. This western blot qualitatively shows that CD44ICD (anti-Flag) co-immunoprecipitated with CREB 
in CD44ICD ZR-75-1 cells. Mouse IgG serves as a negative control. (H) Relative firefly-luciferase activity of PFKFB4 in CREB knockdown ZR-75-1 cells. This graph shows that the relative 
firefly-luciferase activity decreases in CREB knockdown (CREB-sh1 and CREB-sh2) ZR-75-1 cells versus control cells (SC). For (A-D, F), Student’s t-test was used for statistical analysis, for (H), 
one-way ANOVA was used for statistical analysis and data are shown as mean ± SD. Data are representative of at least three independent experiments. 
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Figure 4. PFKFB4 enhances stem cell-like characteristics of breast cancer cells via up-regulation of glycolysis. (A) Analysis of glucose uptake in ZR-75-1 and SKBR3 cells. The 
left graph shows that glucose uptake decreases in PFKFB4 knockdown (PFKFB4-sh1 and PFKFB4-sh2) ZR-75-1 cells versus vector control (SC). The right graph shows that glucose uptake 
increases in PFKFB4 ectopic expression (PFKFB4-WT) SKBR3 cells versus vector control (MCS), while glucose uptake does not increase in PFKFB4 kinase dead mutant ectopic expression 
(PFKFB4-mut) SKBR3 cells versus MCS. (B) Analysis of lactate secretion in ZR-75-1 and SKBR3 cells. (C) Analysis of ROS levels in ZR-75-1 and SKBR3 cells. (D) Western blot analysis of 
SOX2, OCT4, NANOG and PFKFB4 expression in ZR-75-1 and SKBR3 cells. (E) Flow cytometric analysis of ALDH activity in ZR-75-1 and SKBR3 cells. (F) Sphere formation ability of 
ZR-75-1 and SKBR3 cells. (G) Western blot analysis of SOX2, OCT4 and NANOG expression in PFKFB4 ectopic expression (PFKFB4) SKBR3 cells. (H) Flow cytometric analysis of ALDH 
activity in PFKFB4 SKBR3 cells. (I) Sphere formation ability of PFKFB4 SKBR3 cells. One-way ANOVA was used for statistical analysis and data are shown as mean ± SD. Data are 
representative of at least three independent experiments. 
 
PFKFB4 promotes breast cancer stemness via 
enhancing glycolysis and the PFKFB4K173A 
mutation is important for PFKFB4 function 
To further explore the impact of PFKFB4 on 
breast cancer stemness, we performed PFKFB4 
knockdown experiments. We found that PFKFB4 
knockdown in ZR-75-1 breast cancer cells produces 
the following effects: 1) decreases glucose 
consumption and lactate secretion, but enhances ROS 
production (Figure 4A-C); 2) decreases SOX2, OCT4, 
and NANOG expression (Figure 4D); 3) decreases the 
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percentage of ALDEFLUOR+ cells (Figure 4E and 
Figure S3C); and, 4) decreases sphere formation 
ability (Figure 4F and Figure S3D). However, PFKFB4 
ectopic expression in SKBR3 breast cancer cells 
produces the following opposite effects: 1) increases 
glucose consumption and lactate secretion, but 
reduces ROS production (Figure 4A-C); 2) increases 
SOX2, OCT4, and NANOG expression (Figure 4D); 3) 
increases the percentage of ALDEFLUOR+ cells 
(Figure 4E and Figure S3C); and, 4) increases sphere 
formation ability (Figure 4F and Figure S3D). These 
findings indicate that PFKFB4 regulates breast cancer 
stemness via its metabolic function in glycolysis. 
Previous reports indicate that the mutation of Lys173 
to Ala in PFKFB4 results in a reduction of both ATP 
binding and F6P binding [19]. In this regard, we 
found that PFKFB4K173A ectopic expression in SKBR3 
breast cancer cells produces the following effects: 1) 
does not increase glucose consumption and lactate 
secretion, or reduce ROS production (Figure 4A-C); 2) 
does not increase SOX2, OCT4, and NANOG 
expression (Figure 4D); 3) does not increase the 
percentage of ALDEFLUOR+ cells (Figure 4E and 
Figure S3C); and, 4) does not increase sphere 
formation ability (Figure 4F and Figure S3D). These 
findings suggest that the PFKFB4 kinase activity is 
important for both glycolysis and maintenance of 
breast cancer stemness. 
To further confirm that PFKFB4 regulates breast 
cancer stemness via glycolysis, we utilized 
2-deoxy-D-glucose (2-DG), a competitive inhibitor for 
the production of glucose-6-phosphate from glucose. 
Our results showed that 2-DG treatment impedes the 
PFKFB4-mediated increase in SOX2, OCT4, and 
NANOG expression (Figure 4G), the percentage of 
ALDEFLUOR+ cells (Figure 4H and Figure S3E), and 
sphere formation ability in SKBR3 breast cancer cells 
(Figure 4I and Figure S3E). 
PFKFB4 is required for CD44ICD-mediated 
up-regulation of glycolysis and stemness 
To further substantiate that CD44ICD promotes 
breast cancer stemness via PFKFB4, we knocked 
down PFKFB4 in CD44ICD-overexpressed ZR-75-1 
and SKBR3 breast cancer cells. Our results showed 
that a reduction of PFKFB4 in 
CD44ICD-overexpressed ZR-75-1 or SKBR3 cells 
results in the following effects: 1) reduces glucose 
uptake and lactate secretion, and induces ROS 
production (Figure 5A-C); 2) decreases SOX2, OCT4, 
and NANOG expression (Figure 5D); 3) decreases the 
percentage of ALDEFLUOR+ cells (Figure 5E and 
Figure S4A); and 4) decreases sphere formation 
ability (Figure 5F and Figure S4B). In summary, our 
above-mentioned results indicate that CD44ICD 
promotes breast cancer stemness via PFKFB4 (a direct 
downstream molecule of CD44) and its metabolic 
involvement in glycolysis. 
CD44ICD and PFKFB4 expression levels in 
human breast cancer samples are elevated and 
5MPN inhibits breast cancer development 
To substantiate the relevance of our laboratory 
findings to clinical cases, we collected 8 pairs of 
human breast cancer samples that included tumor 
tissue and peri-tumor tissue. We detected elevated 
CD44ICD expression in tumor tissue compared to 
peri-tumor tissue in matched pairs (Figure 6A-B). We 
also found elevated levels of soluble CD44 in 
periphery blood drawn from malignant breast cancer 
patients compared to benign patients, which suggests 
that more CD44 cleavage occurs in malignant patients 
(Figure 6C). Moreover, we detected elevated PFKFB4 
expression levels in tumor tissue compared to 
peri-tumor tissue in matched pairs (Figure 6D). 
Interestingly, elevated PFKFB4 expression levels 
correlate with poor survival outcome based on the 
TCGA dataset (Figure 6E). Most importantly, the 
administration of 5-(n-(8- methoxy-4-quinolyl) amino) 
pentyl nitrate (5MPN; a selective inhibitor of PFKFB4) 
significantly suppressed tumor growth and tumor 
weight in CD44ICD-overexpressed EO771 tumors 
(Figure 6F-G). 5MPN administration also significantly 
attenuated SOX2, OCT4, and NANOG expression in 
CD44ICD-overexpressed EO771 tumors (Figure 6H). 
In addition, administration of 5MPN significantly 
decreased metastatic foci in the lung (Figure 6I). 
These results suggest that 5MPN functions as a 
selective inhibitor of PFKFB4 and inhibits 
CD44ICD-promoted breast cancer development. 
Discussion 
In this study, we found that CD44ICD (the 
cleaved product of CD44) interacts with the CREB 
transcription factor and binds to the promoter region 
of PFKFB4, which thereby regulates PFKFB4 
transcription and expression. The resultant PFKFB4 
expression facilitates the glycolysis pathway (vis-à-vis 
oxidative phosphorylation) and promotes stemness 
features of breast cancer (Figure 7). 
CD44 is a popular marker used to identify and 
enrich stem cells in many different types of cancer 
including breast, colon, liver, ovarian, pancreatic 
cancers [4, 20-23]. However, the exact role of CD44 in 
cancer stem cells remains unclear in part because 
CD44 exists in various isoforms as a result of 
alternative splicing [24]. CD44v isoform expression 
(especially CD44v6) increases in colon, prostate, 
pancreatic, non-small cell lung, and gastric cancers 
[25-29]. In addition, CD44v isoform expression serves 
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as a diagnostic or prognostic marker for tumor 
development [30-34]. CD44s is the shortest CD44 
isoform without insertion of any variant exons and is 
widely expressed in both cancer and normal tissues 
[1]. However, the exact role of CD44s in cancer 
remains unclear since CD44s expression variably 
correlates with an increased likelihood of tumor 
promotion. In addition, CD44s and CD44v6 play 
opposing roles in tumor promotion as shown by 
immunostaining of human breast cancer patient 
samples [35]. And, CD44v isoforms (but not the 
CD44s isoform) promote adenoma initiation in 
Apc(Min/+) mice as indicated by knockin expression 
of either CD44v4-10 isoforms or the CD44s isoform 
[36]. In our studies, we showed that CD44s inhibits 
breast cancer stemness using gain-of-function and 
loss-of-function methods in different models. This 
suggests that CD44v may outperform the effects of 
CD44s and result in tumor development. Moreover, 
Shuo et al. has reported that CD44 knockout in the 
re-programmed liver cancer cell C3A model increases 
CSC stemness and promotes differentiation, which 
confirms our findings via a loss-of-function method 
[37]. 
 
 
Figure 5. PFKFB4 is required for CD44ICD-mediated up-regulation of glycolysis and stemness. (A) Analysis of glucose uptake in ZR-75-1 and SKBR3 cells. This graph shows that 
glucose uptake increases in CD44ICD ectopic expression (ICD-SC) ZR-75-1 and SKBR3 cells versus vector controls (MCS-SC), while glucose uptake decreases in PFKFB4 knockdown ICD 
(ICD-PFKFB4-sh1 and ICD-PFKFB4-sh2) ZR-75-1 and SKBR3 cells versus SC (ICD-SC). (B) Analysis of lactate secretion in ZR-75-1 and SKBR3 cells. (C) Analysis of ROS levels in ZR-75-1 
and SKBR3 cells. (D) Western blot analysis of SOX2, OCT4 and NANOG expression in ZR-75-1 and SKBR3 cells. (E) Flow cytometric analysis of ALDH activity in ZR-75-1 and SKBR3 cells. 
(F) Sphere formation ability of ZR-75-1 cells. One-way ANOVA was used for statistical analysis and data are shown as mean ± SD. Data are representative of at least three independent 
experiments. 
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Figure 6. CD44ICD and PFKFB4 levels correlate with clinical malignancy of breast cancer patients and 5MPN inhibits tumor development. (A) Western blot analysis of 
CD44ICD expression in 8 matched pairs of human breast cancer samples including tumor tissues and peri-tumor tissues. (B) Representative images of CD44ICD immunohistochemical 
staining in 8 matched pairs of human breast cancer samples including tumor tissues and peri-tumor tissues. The graph on the right shows the statistical results. (C) Concentration of soluble 
CD44 in the serum of patients with benign (n=19) or malignant (n=70) breast tumors. (D) Western blot analysis of PFKFB4 expression in 8 matched pairs of human breast cancer samples 
including tumor tissues and peri-tumor tissues. (E) Kaplan-Meier analysis for overall survival of breast cancer patients according to PFKFB4 expression in the TCGA dataset. Low- and 
high-PFKFB4 expression groups were separated according to the mean expression value of all samples studied. The P-value was calculated using the Mantel–Haenszel test. (F) Tumor volume 
of ICD EO771 cells (in a CD44KO genetic background) injected into the 4th fat pad of C57BL/6 mice treated with 5MPN or vehicle control. (G) Tumor weight of ICD EO771 cells (in a 
CD44KO genetic background) injected into the 4th fat pad of C57BL/6 mice treated with 5MPN or vehicle control. (H) Representative images of SOX2, OCT4 and NANOG 
immunohistochemical staining in indicated EO771 tumors from C57BL/6 mice treated with 5MPN or vehicle control (left panel). Quantification of SOX2, OCT4, and NANOG staining based 
on H-score (right panel). (I) Representative images of lung metastasis of ICD EO771 cells (in a CD44KO genetic background) injected into the 4th pair fat pad of C57BL/6 mice treated with 
5MPN or vehicle control (left panel). Quantification of total tumor metastasis to the lung based on incidence of dissemination from primary tumors (right panel). For (B-C), Student’s t-test was 
used for statistical analysis and data are shown as mean ± SD. For (F-I), one-way ANOVA was used for statistical analysis and data are shown as mean ± SEM. Data are representative of at least 
three independent experiments.  
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Figure 7. A proposed model for CD44ICD-mediated regulation of stemness in 
breast cancer cells. CD44ICD is produced upon sequential proteolytic cleavages of 
CD44. The released CD44ICD translocates from the cytoplasm to the nucleus and then 
interacts with CREB to bind to the PFKFB4 promoter region, which causes PFKFB4 
expression. The resultant PFKFB4 promotes breast cancer cell stemness via up-regulation of 
glycolysis. 
 
We also found that CD44ICD promotes tumor 
development via up-regulation of cancer stemness, 
which confirms the findings of Bourguignon et al. [38] 
and Cho et al. [6] that CD44ICD physically associates 
with and activates stem cell markers (i.e., NANOG, 
OCT4, SOX2). CD44ICD translocates into the nucleus 
and regulates the transcription of a number of genes 
in a manner similar to Notch-ICD. Other reports 
demonstrate that the nuclear localization of CD44ICD 
is important for the transcriptional activation of 
various stemness factors (e.g., Nanog, Sox2, Oct4, 
c-Myc) [6, 37]. CD44ICD sustains cell proliferation in 
thyroid cancer and promotes neoplastic 
transformation of rat fibroblasts [18, 39]. More 
importantly, the early responsive genes of CD44ICD 
encode for critical enzymes (e.g., PDK1, PFKFB4) in 
the glycolysis metabolic pathway, which indicates 
that CD44ICD acts as the gatekeeper of the Warburg 
effect [40]. In this regard, we showed that CD44ICD 
functions as a cotranscription factor, interacts with 
CREB binding to the promoter region of PFKFB4, and 
thereby regulates PFKFB4 expression. This 
accumulating evidence suggests that PFKFB4 is an 
early responsive gene of CD44ICD and that PFKFB4 
mediates not only CD44-induced glycolysis but also 
breast cancer stemness.  
The PFKFB4 gene plays the most prominent role 
in the metabolic survival of brain CSCs, as shown by 
RNA interference screening establishing the complete 
human kinome and phosphatome that identify genes 
and pathways relevant for the survival of brain CSCs 
[41]. PFKFB4 deficiency induces AMPK activation, 
which thereby inhibits the mTOR pathway and 
promotes tumor cell apoptosis [36]. In this regard, 
PFKFB4 not only maintains the survival of brain CSCs 
but also associates with a shorter survival time in 
primary glioblastoma patients. PFKFB4 also activates 
the oncogenic steroid receptor co-activator-3 (SRC-3) 
to promote aggressive metastatic breast cancer [42]. 
Moreover, PFKFB4 expression levels are higher in 
prostatic small cell neuroendocrine carcinoma PC-3 
cells that exhibit glycolytic features compared to 
adenocarcinoma LNCaP cells, which suggests 
PFKFB4 involvement in glycolysis [17]. We showed 
that PFKFB4 expression alters glucose consumption, 
lactate secretion, and ROS production of breast cancer 
cells, thereby indicating an alteration of the glycolysis 
pathway. In addition, PFKFB4 expression assists in 
the maintenance of breast cancer stemness by 
impacting the glycolysis metabolic pathway using 
2-DG (a competitive inhibitor for the production of 
glucose-6-phosphate from glucose). Most important, 
we found that Lys173 of PFKFB4 kinase activity plays 
an essential role in the glycolysis metabolic pathway 
and the maintenance of breast cancer stemness. 
Hypoxia is a fundamental pathophysiological 
condition in the microenvironment of solid tumors 
and occurs when the oxygen supply from the 
bloodstream does not meet the cellular demand 
[43-45]. Hypoxia levels correlate with PFKFB4 
expression in human lung adenocarcinoma xenografts 
[46]. In addition, hypoxia levels correlate with 
increased PFKFB4 mRNA and protein expression, 
which are required for hypoxia-induced F2,6P 
production, glucose uptake, and glycolysis. 
Hypoxia-inducible factor 1 (HIF1) is a master 
transcription factor that responds to hypoxia and 
prevents cell differentiation [47]. HIF1α 
trans-activates hypoxia-responsive elements (HRE)-D 
of the PFKFB4 promoter region under hypoxia 
conditions in human bladder cancer cells [48]. In 
addition, HIF1α expression associates with PFKFB4 
expression in human bladder cancer specimens [48]. 
The Gene Ontology analysis of CD44ICD-targeted 
“early response” genes showed that many of the 
genes activated by HIF1α were also activated by 
CD44ICD [40]. So, although hypoxia elicits 
downstream events that lead to the maintenance of 
CSC stemness, CD44ICD also elicits downstream 
events that lead to the maintenance of CSC stemness 
but under both normal oxygen and hypoxia 
conditions. 
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We showed that 5MPN administration 
significantly suppresses tumor growth, tumor weight, 
and lung metastasis in CD44ICD-overexpressed 
EO771 cells using an EO771 murine breast carcinoma 
model. 5MPN was screened as a selective inhibitor of 
PFKFB4 by structure-based virtual computational 
screening and was shown to possess high oral 
bioactivity. 5MPN suppresses glycolysis and 
proliferation in multiple human cancer cell lines, but 
not in non-transformed epithelial cells in vitro. 
Furthermore, 5MPN suppresses glucose uptake and 
tumor growth in mice injected with Lewis lung 
carcinoma cells [49]. PFKFB4 is not only a key 
participant in the glycolysis metabolic pathway, but 
also shows high expression levels in many different 
cancers [50-53]. Consequently, this allows us to 
speculate that a clinical trial using 5MPN either as a 
single agent or in combination with currently 
available treatment may lead to an improved 
therapeutic outcome for cancer patients. 
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